Newron Pharmaceuticals S.p.A. (OTCMKTS:NWPHF) Short Interest Up 44.9% in April

Newron Pharmaceuticals S.p.A. (OTCMKTS:NWPHF) was the target of a significant growth in short interest in April. As of April 15th, there was short interest totaling 162,794 shares, a growth of 44.9% from the March 31st total of 112,375 shares. Based on an average trading volume of 25 shares, the short-interest ratio is currently 6,511.8 days. Currently, 0.9% of the shares of the stock are short sold.

Newron Pharmaceuticals Stock Performance

OTCMKTS:NWPHF opened at $20.00 on Tuesday. Newron Pharmaceuticals has a 12-month low of $9.10 and a 12-month high of $20.00. The stock has a 50-day moving average price of $13.62 and a 200 day moving average price of $10.86.

About Newron Pharmaceuticals

Newron Pharmaceuticals SpA is a clinical-stage biopharmaceutical company headquartered in Bresso, Italy, dedicated to developing novel therapies for central nervous system (CNS) disorders. The company’s research and development efforts focus on small-molecule compounds designed to address unmet medical needs in neurology and psychiatry.

Newron’s lead product, safinamide, is marketed under the brand name Xadago as an adjunctive therapy for patients with mid- to late-stage Parkinson’s disease.